Welcome to our dedicated page for ImageneBio SEC filings (Ticker: IMA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The ImageneBio, Inc. (neBio, Inc., Nasdaq: IMA) SEC filings page on Stock Titan aggregates the company’s U.S. regulatory disclosures, giving investors direct access to official information about this clinical-stage biotechnology issuer. neBio focuses on therapeutics for immunological, autoimmune, and inflammatory diseases, and its filings provide context on the development of its lead asset, -007, an investigational non-depleting anti-OX40 monoclonal antibody.
Through this page, users can review current reports on Form 8-K that document material events such as the completion and subsequent amendment of the merger between Inmagene Biopharmaceuticals and Ikena Oncology, Inc., changes in executive officers and directors, entry into or modification of material agreements, and the announcement of quarterly financial results. These filings also confirm that neBio’s common stock, with a par value of $0.001 per share, is registered under Section 12(b) of the Exchange Act and trades on The Nasdaq Capital Market under the symbol IMA.
Investors can also locate neBio’s registration statement on Form S-1, which contains detailed descriptions of the company’s business, risk factors, and financial statements, including discussion of how historical financial data were adjusted to reflect the recapitalization associated with the merger. As the company advances -007 through clinical development, periodic and current reports provide additional insight into research and development spending, corporate structure, and key risk disclosures.
Stock Titan enhances these filings with AI-powered summaries that explain the significance of each document in accessible language. Users can quickly understand the main points of lengthy reports while retaining the option to open the full SEC filing text for deeper review, helping them follow IMA’s regulatory and corporate history with less manual effort.
ImageneBio amended its current report to provide additional disclosure about the acquired business, Inmagene. The amendment adds Management's Discussion and Analysis for Inmagene and unaudited interim condensed financial statements covering the three- and six-month periods ended June 30, 2025 and 2024. The filing incorporates these items as Exhibits 99.3 and 99.4 and states it does not change any other previously reported items or discuss developments after the original report. The disclosure supplements the Original Report that had reported completion of the Merger.